Mingjun Xu

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong et al. · The Lancet · 2016 · 515 citations

Cisplatin Versus Fluorouracil, Medicine, Metronomic Therapy +6

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 429 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +8

Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study

Mei Zhang, Yan Liu, Mingjun Xu et al. · Scientific Reports · 2019 · 112 citations · Full text

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study

Shaodong Hong, Yaxiong Zhang, Gengsheng Yu et al. · Journal of Clinical Oncology · 2021 · 95 citations · Full text

Echocardiographic Measurements in Normal Chinese Adults Focusing on Cardiac Chambers and Great Arteries: A Prospective, Nationwide, and Multicenter Study

Guihua Yao, Yan Deng, Yan Liu et al. · Journal of the American Society of Echocardiography · 2015 · 93 citations

Hypertension, Cardiovascular Epidemiology, Cardiovascular Disease +13